Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
Categories (click each to see list of all clinical trials associated with that category): Lymphoma/CLL (ONC)
Current Status: Open
Phase: II (Cancer Control)
Principal Investigator: D'Angelo, Christopher
Contact Information:
Katie Bourret
kbourret@unmc.edu
Summary
Primary
To compare zilovertamab vedotin plus R-CHP with polatuzumab vedotin plus R-CHP with respect to CR rate at EOT per Lugano response criteria as assessed by BICR.
Secondary
To compare zilovertamab vedotin plus R-CHP with polatuzumab vedotin plus R-CHP with respect to PFS per Lugano response criteria as assessed by BICR.
To compare zilovertamab vedotin plus R-CHP with polatuzumab vedotin plus R-CHP with respect to OS.
To evaluate EFS with zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP per Lugano response criteria as assessed by BICR.
To evaluate the DurCR of zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP per Lugano response criteria as assessed by BICR.
To evaluate the safety and tolerability of zilovertamab vedotin plus R-CHP.
To evaluate change from baseline in HRQoL and symptoms using the FACT-Lym and FACT/GOG-NTX.